Skip to main navigation Skip to search Skip to main content

A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients with Adenosine Deaminase (ADA)-Deficient Combined Immunodefiency

Project: Research

Project Details

StatusFinished
Effective start/end date12/1/16 → 06/30/21

Funding

  • Sigma-Tau Pharmaceuticals Incorporated: $95,163.35